Cash and cash equivalents: As of September 30, 2025, the Company had cash and cash equivalents of approximately $6.4 million, compared to approximately $21.3 million as of December 31, 2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRAW:
- Traws Pharma’s New COVID-19 Drug Trial: A Potential Game-Changer?
- Traws Pharma’s TRX-100 Study: A Potential Game-Changer in Pharmacokinetics
- Traws Pharma Approves Executive Stock Options Grant
- Traws Pharma Begins Phase 2 COVID-19 Treatment Study
- Traws Pharma doses first patient with ratutrelvir in Phase 2 COVID studies